Ten to 15 years ago, I had to constantly clear my throat and it was driving me and everybody around me nuts. You had written a column ...

The most common causes of chronic cough include gastroesophageal reflux disease (GERD), asthma, and postnasal drip (also known as upper airway cough syndrome), said Sean Duffy, MD, an associate ...

Adults with refractory chronic cough who received twice-daily camlipixant had decreases in cough frequency and better scores assessing cough severity and cough-related quality of life at day 28 from ...

Merck's stock trades at a low valuation as investors worry about Keytruda's looming patent cliff. The company is looking to a new, subcutaneous formulation, which could help sales remain strong ...

40% of Merck & Co., Inc.'s revenues are driven by cancer med Keytruda, which faces patent expiry by 2028, posing a significant risk to future earnings and share price value. The company is ...

Merck MRK announced that it has entered into an exclusive licensing deal with China-based Jiangsu Hengrui Pharmaceuticals (Hengrui Pharma) for the latter’s investigational oral small-molecule ...

Health experts have warned that a cough lasting more than three weeks could be a sign of a deadly disease making a comeback in the UK. The most recent data from the UK Health Security Agency ...

Merck & Co. will pay as much as $2 billion for the rights to Jiangsu Hengrui Pharmaceuticals Co.’s experimental heart drug, the US drugmaker’s second recent foray into China for a novel medicine.

Merck (MRK) has signed a licensing agreement for a heart disease drug developed by a Chinese company in a deal worth up to $2 billion, the latest in a series of cross-border deals between Western ...

Imperial College London says that way more of us than you might think (one in 10 Brits) have a “chronic”, or ongoing, cough. The issue may persist for “decades,” they say, and is more ...

Merck & Co. is handing over $200 million to China’s Hengrui Pharma for a phase 2-stage lipoprotein(a) (Lp(a)) inhibitor. In return for the ex-China rights to the drug, dubbed HRS-5346, Merck has ...